Диссертация (1140655), страница 25
Текст из файла (страница 25)
– 1996. – Vol. 87(5, part 1). – P.715–721.14.Lagace E.A., Hansen W., Hickner J.M. Prevalence and severity of urinaryincontinence in ambulatory adults: an UPRNet study //Journal of FamilyPractice. –1993. – Vol. 36(6). – P. 610–614.15.Ouslander J.G., Kane R.L., Abrass I.B. Urinary incontinence in elderlynursing home patients//Journal of the American Medical Association. – 1982.– Vol.248(10). – P.
1194–1198.16.Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S. A medium termanalysis of the subjective efficacy of treatment for women with detrusorinstability and low bladder compliance //British Journal of Obstetrics andGynaecology. –1997. – Vol. 104(9). – P. 988–993.17.Homma Y., Paick J.S., Lee J.G., Kawabe K. Clinical efficacy and tolerabilityof extended-release tolterodine and immediate-release oxybutynin inJapanese and Korean patients with an overactive bladder: a randomized,placebo-controlled trial//BJU Int.
–2003. – Vol. 92(7). – P.741–747.18.Аль-Шукри С. Х., Кузьмин И. В.Императивныепозывыкмочеиспусканию — ведущий симптом гиперактивности мочевогопузыря / В сб.: Материалы IV Международной научно-практической165конференции «Малоинвазивные методы диагностики и лечения всовременной урологии». – С-Петербург, 2007. – C. 31–32.19.Аляев Ю. Г., Балан В. Е., Гаджиева З. К.Распространенностьимперативных нарушений мочеиспускания среди женщин старше 40лет / В сб.: Материалы Пленума Всероссийского о-ва урологов.
–Тюмень, 2005. – C. 356–357.20.Кузьмин И. В. Оценка качества жизни у больных с гиперактивностьюмочевого пузыря // Нефрол. – 2006. – Т. 10, № 4. – С. 93–97.21.Tran K., Levin R.M., Mousa S.M. Behavioral Intervention versusPharmacotherapy or Their Combinations in the Management of OveractiveBladder Dysfunction //The Pharmaceutical Research Institute. – AlbanyCollege of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA. –July 7, 2009.22.Кузьмин И.В., Аль-Шукри С.Х. Классификация гиперактивностимочевого пузыря при степени тяжести симптоматики // Урологическиеведомости. – 2012.
– Т. 2, №3. – С.3-7.23.Liu H.T., Chancellor M.B., Kuo H.C. Urinary nerve growth factor levels areelevated in patients with detrusor overactivity and decreased in responders todetrusor botulinum toxin-A injection //Eur. Urol. – 2009 Oct. – Vol. 56(4). –P. 700-6.24.Lowe E.M., Anand P., Terenghi G.
et al. Increase nerve growth factor levelsin the urinary bladder of women with idiopathic sensory urgency andinterstitial cyctitis // Br J Urol. – 1997. – Vol. 79. – P. 572-7.25.Okragly A.J., Niles A.L., Saban R., et al. Elevated tryptase, nerve growthfactor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels inthe urine of interstitial cyctitis and bladder cancer patients // J Urol. – 1999.– Vol. 161. – P. 438-41.26.Лоран О.Б.,ВишневскийЕ.А.,ВишневскийА.Е.Роль гипоксии детрузора в патогенезе расстройств мочеиспускания у166больных доброкачественной гиперплазией предстательной железы //Урология и нефрология. – 1996. – № 6. – С.
33-37.27.Лоран О.Б.,ВишневскийС.М. Ультраструктурные исследованияА.Е.,детрузораСекамоваубольныхсдоброкачественной гиперплазией предстательной железы // Урология инефрология. – 1996. – № 4. – С. 27-31.28.Michel M.C.,Chapple C.R.Basic mechanisms of urgency: preclinical andclinical evidence //Eur. Urol.– 2009 Aug. – Vol. 56(2). – P. 298-307.29.Cucchi A., Quaglini S., Rovereto B. Relationships between micturitionurgency and involuntary voiding dynamics in men with urinary incontinencefrom idiopathic detrusor overactivity // J Urol. –2007. – Vol.178.
– P. 563567.30.Cucchi A., Quaglini S., Siracusano S. et al. Urgency degree and bladdercontraction velocity: sequential changes in women with idiopathic detrusoroveractivity // Neurourol Urodyn. – 2006. – Vol. 25. – P. 123-127.31.Speakman M.J., Brading A.F., Gilpin C.J. et al. Bladder outflow obstruction– a case of denervation supersensetivity // J. Urol. – 1987. – Vol. 138. – P.1461-1466.32.Boselini C., Govoni S., Condino A.M., D’Agostino G.
Bladder instability: areappraisal of classical experimental approaches and development of newtherapeutic strategies // J Auton Pharmacol. – 2001. – Vol. 21. – P. 219-229.33.Southgate J., Varley C.L., Garthwaite M.A. et al. Differentiation potential ofurothelium from patients with benign bladder dysfunction //BJU Int.– 2007Jun. – Vol.
99(6). – P.1506-16.34.Varley C.L., Gartwaite M.A., Cross W. et al. PPARγ-regulated tightingection development during human urothelial cytodifferentiation // J CellPhisiol. – 2006. – Vol. 208. – P. 407-17.35.Hu P., Meyers S., Liang F.X. et al. Role of membrane proteins inpermeability barrier function: uroplakin ablation elevates urothelialpermeability // Am J physiol Renal Physiol.
– 2002. – Vol. 283. – P. 1200-7.16736.Yoshida M., Masunaga K., Nagata T. et al. The forefront for noveltherapeutic agents based on the pathophysiology of lower urinary tractdysfunction: pathophysiology and pharmacotherapy of overactive bladder. //J Pharmacol Sci. – 2010 Feb. – Vol. 112(2). – P.
128-34.37.Cheng Y., Mansfield K.J., Allen W. et al. Does adenosine triphosphate intovoided urodynamic fluid contribute to urgency signaling in women withbladder dysfunction? // J.Urol. – 2010 Mar. – Vol 183 (3). – P. 1082-6.38.Пушкарь Д.Ю., Зайцев А.В., Раснер П.И. и соавт. Этиология, патогенези методы определения ургентного мочеиспускания // Урология. – 2010.- №3. – С. 61-68.39.Родионов И.М.
Фактор роста нервов, гипертрофия и деструкциясимпатическойсистемывэксперименте//Соросовскийобразовательный журнал. – 1996. – №3. – С. 17-22.40.Steers W.D., Kolbeck S., Creedon D., Tuttle J.B. Nerve growth factor in theurinary bladder of the adult regulates neuronal form and function // J ClinInvest.
– 1991. – Vol. 88. – P. 1709-15.41.Tuttle J.B., Streers W.D., Albo M., Nataluk E. Neural input regulates tissueNGF and growth of the adult urinary bladder // J Auton Nerv Syst. – 1994. –Vol. 49. – P. 147-58.42.Dupont M.C., Spitsberegen J.M., Kim K.B. et al. Histological andneuroyrophic changes triggered by varying models of bladder inflammation// J Urol. – 2001. – Vol. 166.
– P. 1111-8.43.Yokoyama T., Kumon H., Nagai A. Correlation of urinary nerve growthfactor level with pathogenesis of overactive bladder //Neurourol Urodyn. –2008. – Vol. 27(5). – P. 417-20.44.Yoshida M., Inadome A., Maeda Y., et al. Non-neuronal cholinergic systemin human bladder urothelium // Urology. – 2006. – Vol. 67. – P.
425-430.45.De Groat W.C. The urothelium in overactive bladder: Passive bystander oractive participant? // Urology. – 2004. – Vol. 64. – P. 7-11.16846.Hawthorn M.H., Chapple C.R., Cock M., Chess-Williams R. Urotheliumderived inhibitory factor(s) influence detrusor muscle contractility in vitro.Br J Pharmacol. 2000; 129: 416-419.47.Mansfield K.J., Liu L., Mitchelson F.J. et al. Muscarinic receptor subtype inhuman bladder detrusor and mucosa, studied by radiological binding andquantitative competitive RT-PCR: changes in aging // Br J Pharmacol.
–2005. – Vol. 144. – P. 1089-1099.48.Mikerji G., Yiangou Y., Grogono J. et al. Localization of M2 and M3muscarinic receptors in human bladder disorders and their clinicalcorrelations // J Urol. – 2006. – Vol.176. – P. 367-373.49.Lee S.R., Kim H.J., Kim A., Kim J.H.: Overactive bladder is not onlyoveractive but also hypersensitive // Urology.
– 2010 May. – Vol.75 (5). – P.1053-9.50.Nomiya M., Yamaguchi O. A quantitative analysis of mRNA expression ofalpha 1 and beta adrenoceptor subtypes and their functional roles in humannormal and obstructed bladders // J Urol. – 2003. – Vol. 170. – P. 649–653.51.Yamaguchi O., Chapple C.R.: Beta3-adrenoreceptors in urinary bladder //Neurourol Urodyn. – 2007.
– Vol. 26. – P. 752-756.52.Yoshimura N., Kaiho Y., Miyazato M. et al. Therapeutic receptor targets forlower urinary tract dysfunction // Naunyn-Schmiedeberg’s Arch Pharmacol.– 2008. – Vol. 377. – P. 437–448.53.Kubota Y., Biers S.M., Kohri K., Brading A.F.Effects of imatinib mesylate(Glivec) as a c-kit tyrosine kinase inhibitor in the guinea-pig urinary bladder//NeurourolUrodyn. – 2006.
– Vol. 25 (3). – P. 205–210.54.Y. Kubota, S. Kajioka, S. M. Biers, et al. Investigation of the effect of the ckit inhibitor Glivec on isolated guinea-pig detrusor preparations //AutonomicNeuroscience – 2004. – Vol. 115 (2). – P. 64–73.55.Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российскиеклинические рекомендации. – М.: ГЭОТАР-Медицина, 2015. – 480 с.16956.Greenberg P., Brown J., Yates T., et al. Voiding urges perceived by patientswith interstitial cystitis/painful bladder syndrome //Neurourol Urodyn. –2008.
– Vol. 27(4). – P. 287-90.57.Abrams P. Urgency: Thefey to defining the overactive bladder // Br J UrolInt. – 2005. – Vol. 96. – P. 1-3.58.Barber M.D. Questionnaires for women with pelvic floor disorders // Int.Urogynecol. J. Pelvic Floor Dysfunct. – 2007. – Vol. 18. – P. 461-465.59.Chapple C.R., Artibani W., Cardozo L.D. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
